[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0517737A - inibidores de quinase - Google Patents

inibidores de quinase

Info

Publication number
BRPI0517737A
BRPI0517737A BRPI0517737-5A BRPI0517737A BRPI0517737A BR PI0517737 A BRPI0517737 A BR PI0517737A BR PI0517737 A BRPI0517737 A BR PI0517737A BR PI0517737 A BRPI0517737 A BR PI0517737A
Authority
BR
Brazil
Prior art keywords
aurora
kinase inhibitors
compositions
compounds
methods
Prior art date
Application number
BRPI0517737-5A
Other languages
English (en)
Inventor
Xiao-Yi Xiao
Dinesh V Patel
Original Assignee
Miikana Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miikana Therapeutics Inc filed Critical Miikana Therapeutics Inc
Publication of BRPI0517737A publication Critical patent/BRPI0517737A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

INIBIDORES DE QUINASE. São descritas inibidores da proteína quinase de Fórmula Ia e Ib, composições que compreendem tais inibidores, e os métodos de uso, dos mesmos. Mais em particular, esses compostos e as composições são inibidores de proteína quinase Aurora-A (Aurora-2) e Aurora-B (Aurora-l) . São também revelados métodos de usar esses compostos e composições para prevenir e tratar doenças associadas com as proteínas quinases, especialmente as doenças associadas com Aurora-A ou Aurora-B, tal como o câncer.
BRPI0517737-5A 2004-11-17 2005-11-17 inibidores de quinase BRPI0517737A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62917604P 2004-11-17 2004-11-17
PCT/US2005/041945 WO2006055831A2 (en) 2004-11-17 2005-11-17 Kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0517737A true BRPI0517737A (pt) 2008-10-21

Family

ID=36407795

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517737-5A BRPI0517737A (pt) 2004-11-17 2005-11-17 inibidores de quinase

Country Status (13)

Country Link
US (1) US8153630B2 (pt)
EP (1) EP1812424A4 (pt)
JP (1) JP2008520713A (pt)
KR (1) KR20070086188A (pt)
CN (1) CN101084214A (pt)
AU (1) AU2005306458B2 (pt)
BR (1) BRPI0517737A (pt)
CA (1) CA2587427A1 (pt)
IL (1) IL183276A0 (pt)
MX (1) MX2007005857A (pt)
NO (1) NO20073024L (pt)
RU (1) RU2007122485A (pt)
WO (1) WO2006055831A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2540987T3 (es) 2004-05-14 2015-07-15 Millennium Pharmaceuticals, Inc. Métodos para preparar inhibidores de la aurora cinasa
CA2587427A1 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
JP5597353B2 (ja) * 2005-09-30 2014-10-01 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
US7948440B1 (en) 2006-09-30 2011-05-24 LHC2 Inc. Horizontally-polarized omni-directional antenna
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CN101638808B (zh) * 2008-07-31 2012-10-17 复旦大学 筛选加强型抗肿瘤化合物的方法
KR101741168B1 (ko) 2008-12-22 2017-05-29 밀레니엄 파머슈티컬스 인코퍼레이티드 오로라 키나아제 억제제 및 항­ｃｄ 항체의 병용
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
CA2764983A1 (en) * 2009-06-10 2010-12-16 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
CA2788774A1 (en) 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate
WO2013138617A1 (en) 2012-03-16 2013-09-19 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CA2907726A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
US20170224819A1 (en) 2014-08-11 2017-08-10 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor
US20170239351A1 (en) 2014-08-11 2017-08-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
PT3179991T (pt) 2014-08-11 2021-11-26 Acerta Pharma Bv Combinações terapêuticas de um inibidor de btk e um inibidor de bcl-2
EP3200881A1 (en) 2014-09-30 2017-08-09 Avon Products, Inc. Topical compositions and methods for skin lightening
AU2015369690B2 (en) 2014-12-23 2019-01-17 SMA Therapeutics Inc. 3,5-diaminopyrazole kinase inhibitors
EP3324976A4 (en) 2015-07-21 2019-03-27 Millennium Pharmaceuticals, Inc. ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
CN118255713A (zh) * 2022-12-28 2024-06-28 深圳微芯生物科技股份有限公司 一种萘酰胺类化合物、其制备方法及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57203072A (en) 1981-06-05 1982-12-13 Sankyo Co Ltd 4-anilinopyrimidine derivative, its preparation, antidepressant comprising it as active ingredient
JPH0665237A (ja) 1992-05-07 1994-03-08 Nissan Chem Ind Ltd 置換ピラゾール誘導体および農園芸用殺菌剤
US5453414A (en) 1993-05-20 1995-09-26 Rohm And Haas Company 2-arylpyrimidines and herbicidal use thereof
EP0640599B1 (en) 1993-08-26 1998-03-04 Ono Pharmaceutical Co., Ltd. 4-Aminopyrimidine derivatives
CA2203517A1 (en) * 1994-11-10 1996-05-23 Alan M. Laibelman Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
DE19511562A1 (de) 1995-03-29 1996-10-02 Hoechst Schering Agrevo Gmbh Cyclohexylamino- und alkoxy-Stickstoff-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US6200977B1 (en) * 1998-02-17 2001-03-13 Tularik Inc. Pyrimidine derivatives
ES2241324T3 (es) 1998-10-08 2005-10-16 Astrazeneca Ab Derivados de quinazolina.
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
WO2001056993A2 (en) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
JP2003532635A (ja) 2000-02-17 2003-11-05 アムジエン・インコーポレーテツド キナーゼ阻害薬
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CA2398446A1 (en) * 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
EP1303495B1 (en) * 2000-07-24 2010-05-26 Krenitsky Pharmaceuticals, Inc. Substituted 5-alkynyl pyrimidines having neurotrophic activity
AP2001002266A0 (en) 2000-08-31 2001-09-30 Pfizer Prod Inc Pyrazole derivatives.
KR20030030005A (ko) * 2000-09-15 2003-04-16 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CN1474815A (zh) 2000-09-20 2004-02-11 Ĭ��ר���ɷ����޹�˾ 4-氨基-喹唑啉
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
CN100340555C (zh) 2000-12-21 2007-10-03 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
MXPA03009378A (es) * 2001-04-13 2004-01-29 Vertex Pharma Inhibidores de cinasas c-jun n-terminales (jnk) y otras proteinas cinasas.
EP1404669A2 (en) * 2001-05-16 2004-04-07 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
MXPA03010961A (es) 2001-05-31 2004-02-27 Vertex Pharma Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
JP4541695B2 (ja) 2001-06-15 2010-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとしての５−（２−アミノピリミジン−４−イル）ベンズイソキサゾール
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
MXPA04001088A (es) 2001-08-03 2004-05-20 Vertex Pharma Derivados de pirazol como inhibidores de cinasa y uso de los mismos.
MXPA04006260A (es) 2001-12-24 2005-03-31 Astrazeneca Ab Derivados de quinazolina sustituidos como inhibidores de cinasas aurora.
ATE466580T1 (de) 2002-03-15 2010-05-15 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
DE60327999D1 (de) 2002-03-15 2009-07-30 Vertex Pharma Azolylaminoazine als inhibitoren von proteinkinasen
AU2003218215A1 (en) 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
DE60314603T2 (de) 2002-03-15 2008-02-28 Vertex Pharmaceuticals Inc., Cambridge Zusammensetzungen brauchbar als protein-kinase-inhibitoren
US6677337B2 (en) * 2002-03-19 2004-01-13 The Procter & Gamble Company 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines
US20030207873A1 (en) * 2002-04-10 2003-11-06 Edmund Harrington Inhibitors of Src and other protein kinases
ES2340475T3 (es) 2002-05-01 2010-06-04 Vertex Pharmaceuticals Incorporated Estructura cristalizada de proteina aurora-2 y sus bolsillos de union.
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
JP4570955B2 (ja) * 2002-07-09 2010-10-27 バーテクス ファーマスーティカルズ インコーポレイテッド プロテインキナーゼ阻害活性を持つイミダゾール類
US20040023977A1 (en) 2002-07-15 2004-02-05 Larsen Robert D. Process for making substituted thiazolyl-amino pyrimidinyl
US7482355B2 (en) 2002-08-24 2009-01-27 Astrazeneca Ab Pyrimidine derivatives as modulators of chemokine receptor activity
WO2004037814A1 (en) 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
WO2004105764A1 (en) 2003-06-02 2004-12-09 Astrazeneca Ab (3- ((quinazolin-4-yl) amino )-1h-pyrazol-1-yl) acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
BRPI0415398A (pt) 2003-10-17 2006-12-19 Astrazeneca Ab composto, composição farmacêutica, processo para a preparação da mesma, uso de um composto, método de tratamento de cáncer, e, processo para preparação de um composto
CN100554264C (zh) 2003-11-24 2009-10-28 弗·哈夫曼-拉罗切有限公司 吡唑基与咪唑基嘧啶
WO2005068468A2 (en) 2003-12-02 2005-07-28 Vertex Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors and uses thereof
AR049418A1 (es) 2004-02-27 2006-08-02 Bayer Pharmaceuticals Corp Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
CA2587427A1 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
US20060142572A1 (en) 2004-12-14 2006-06-29 Gabriel Martinez-Botella Inhibitors of ERK protein kinase and uses thereof

Also Published As

Publication number Publication date
EP1812424A2 (en) 2007-08-01
MX2007005857A (es) 2007-10-10
IL183276A0 (en) 2007-10-31
JP2008520713A (ja) 2008-06-19
EP1812424A4 (en) 2009-07-08
NO20073024L (no) 2007-07-02
CA2587427A1 (en) 2006-05-26
RU2007122485A (ru) 2008-12-27
AU2005306458B2 (en) 2011-02-17
CN101084214A (zh) 2007-12-05
AU2005306458A1 (en) 2006-05-26
US8153630B2 (en) 2012-04-10
WO2006055831A3 (en) 2006-12-07
US20080200485A1 (en) 2008-08-21
WO2006055831A2 (en) 2006-05-26
KR20070086188A (ko) 2007-08-27

Similar Documents

Publication Publication Date Title
BRPI0517737A (pt) inibidores de quinase
BRPI0616630B8 (pt) compostos de pirazol substituídos
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
TW200801008A (en) Protein kinase inhibitors
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
CL2011001215A1 (es) Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
BRPI0417708A (pt) derivados organofosfóricos dos indazóis e sua utilização como inibidores das proteìnas quinases
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
ATE499364T1 (de) Hemmer der akt aktivität
BRPI0814065B8 (pt) derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
ATE469151T1 (de) Pyrrolopyridinderivate als proteinkinaseinhibitoren
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
EA201100425A1 (ru) Производные пиколинамида в качестве ингибиторов киназы
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
NO20071915L (no) Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
GEP20125368B (en) Kinase inhibitors
BRPI0821743B8 (pt) derivados de piridazinona, e seu uso
BRPI0517921A (pt) métodos para preparar compostos de indazol
EA200970041A1 (ru) Ингибиторы акт (протеинкиназы в)
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.